SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 12, 2017

SCYNEXIS, Inc. to Present at the 16th Annual Needham Healthcare Conference

Mar 29, 2017

SCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update

Mar 13, 2017

SCYNEXIS, Inc. to Present at the 29th Annual ROTH Conference

Mar 7, 2017

SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request

Mar 2, 2017

SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

Jan 31, 2017

SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors

Jan 26, 2017

SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections

Dec 13, 2016

SCYNEXIS, Inc. to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference

Dec 12, 2016

SCYNEXIS, Inc. Reports Third Quarter 2016 Financial Results and Provides Company Update

Nov 7, 2016